ALB and hypertriglyceridemia: We previously reported that pemafibrate significantly reduced serum levels of AST, ALT and GGT and significantly increased serum albumin levels at 3, 6 and 12 months after the start of pemafibrate treatment in patients with hypertriglyceridemia, which was associated with a reduction in atherogenic dyslipidemia [82].